The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts
14 analysts have shared their evaluations of Blueprint Medicines (NASDAQ:BPMC) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 7 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 3 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $129.14, a high estimate of $150.00, and a low estimate of $100.00. This upward trend is evident, with the current average reflecting a 0.56% increase from the previous average price target of $128.42.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of Blueprint Medicines's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Judah Frommer | Morgan Stanley | Lowers | Equal-Weight | $100.00 | $120.00 |
| Michael Yee | Jefferies | Announces | Buy | $135.00 | - |
| Louise Chen | Scotiabank | Announces | Sector Outperform | $150.00 | - |
| Reni Benjamin | Citizens Capital Markets | Maintains | Market Outperform | $125.00 | $125.00 |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $125.00 | $125.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $135.00 | $135.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Brian Cheng | JP Morgan | Raises | Overweight | $129.00 | $126.00 |
| Christopher Raymond | Piper Sandler | Raises | Neutral | $119.00 | $109.00 |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $125.00 | $125.00 |
| David Nierengarten | Wedbush | Lowers | Outperform | $124.00 | $135.00 |
| Ami Fadia | Needham | Maintains | Buy | $135.00 | $135.00 |
| Sudan Loganathan | Stephens & Co. | Maintains | Overweight | $140.00 | $140.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Blueprint Medicines's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Blueprint Medicines's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Blueprint Medicines analyst ratings.
Get to Know Blueprint Medicines Better
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Financial Insights: Blueprint Medicines
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Blueprint Medicines showcased positive performance, achieving a revenue growth rate of 103.41% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Blueprint Medicines's net margin excels beyond industry benchmarks, reaching -34.13%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Blueprint Medicines's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -16.33%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Blueprint Medicines's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.2%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Blueprint Medicines's debt-to-equity ratio stands notably higher than the industry average, reaching 1.57. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Core of Analyst Ratings: What Every Investor Should Know
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.